1. pregnant or lactating females 2. participation in any clinical trial with intake of any nonregistered vaccine product 3. any concomitant disease affecting the effect of the therapeutic vaccine or interfering with the study primary endpoint: * active infection * psychiatric disorders * known systemic anaphylaxis 4. prior or current infection with sars-cov-2 as assessed by medical history and/or by throat/nose swab (pcr) or serologically documented immunization against sarscov- 2 (after infection or vaccination) 5. persisting symptoms developed after sars-cov-2 vaccination with an approved vaccine product at study inclusion 6. history of guillain-barré syndrome 7. hiv infection, chronic or active hepatitis b or c 8. history of relevant cns pathology or current relevant cns pathology (e.g. seizure, paresis, aphasia, cerebrovascular ischemia/haemorrhage, severe brain injuries, dementia, parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder, excluding febrile seizures as child) 9. baseline laboratory cd4+ t cell count \< 100 μl 10. the following pre-existing medical conditions: * chronic liver failure defined as child-pugh score ≥b * chronic renal failure defined as gfr \<40 ml/min/1,73m2 * serious pre-existing cardiovascular disease such as nyha ≥ iii * sickle cell anemia 11. patients presenting with any clinical, laboratory or radiological signs of tumor-progression 12. patient receiving active treatment with small molecules, including tyrosine kinases-inhibitors (e.g. ibrutinib), proteosome-inhibitors (e.g. bortezomib), bcl-2- inhibitors (e.g. venetoclax), phosphoinositid-3-kinase- inhibors (e.g. idelalisib) 13. known hypersensitivity to any of the components included in the covac-1 vaccine 14. pre-existing auto-immune disease except for hashimoto thyroiditis and mild (not requiring immunosuppressive treatment) psoriasis 15. intention of receiving one dose of an already approved vaccine against sars-cov-2 before day 56

1. pregnant or lactating females 2. participation in any clinical trial with intake of any nonregistered vaccine product 3. any concomitant disease affecting the effect of the therapeutic vaccine or interfering with the study primary endpoint: * active infection * psychiatric disorders * known systemic anaphylaxis 4. prior or current infection with sars-cov-2 as assessed by medical history and/or by throat/nose swab (pcr) or serologically documented immunization against sarscov- 2 (after infection or vaccination) 5. persisting symptoms developed after sars-cov-2 vaccination with an approved vaccine product at study inclusion 6. history of guillain-barré syndrome 7. hiv infection, chronic or active hepatitis b or c 8. history of relevant cns pathology or current relevant cns pathology (e.g. seizure, paresis, aphasia, cerebrovascular ischemia/haemorrhage, severe brain injuries, dementia, parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder, excluding febrile seizures as child) 9. baseline laboratory cd4+ t cell count \< 100 μl 10. the following pre-existing medical conditions: * chronic liver failure defined as child-pugh score ≥b * chronic renal failure defined as gfr \<40 ml/min/1,73m2 * serious pre-existing cardiovascular disease such as nyha ≥ iii * sickle cell anemia 11. patients presenting with any clinical, laboratory or radiological signs of tumor-progression 12. patient receiving active treatment with small molecules, including tyrosine kinases-inhibitors (e.g. ibrutinib), proteosome-inhibitors (e.g. bortezomib), bcl-2- inhibitors (e.g. venetoclax), phosphoinositid-3-kinase- inhibors (e.g. idelalisib) 13. known hypersensitivity to any of the components included in the covac-1 vaccine 14. pre-existing auto-immune disease except for hashimoto thyroiditis and mild (not requiring immunosuppressive treatment) psoriasis 15. intention of receiving one dose of an already approved vaccine against sars-cov-2 before day 56

pregnant or lactating females participation in any clinical trial with intake of any nonregistered vaccine product any concomitant disease affecting the effect of the therapeutic vaccine or interfering with the study primary endpoint: active infection psychiatric disorders known systemic anaphylaxis prior or current infection with sars-cov-2 as assessed by medical history and/or by throat/nose swab (pcr) or serologically documented immunization against sarscov- 2 (after infection or vaccination) persisting symptoms developed after sars-cov-2 vaccination with an approved vaccine product at study inclusion history of guillain-barré syndrome hiv infection, chronic or active hepatitis b or c history of relevant cns pathology or current relevant cns pathology (e.g. seizure, paresis, aphasia, cerebrovascular ischemia/haemorrhage, severe brain injuries, dementia, parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder, excluding febrile seizures as child) baseline laboratory cd4+ t cell count < 100 μl the following pre-existing medical conditions: chronic liver failure defined as child-pugh score ≥b chronic renal failure defined as gfr <40 ml/min/1,73m2 serious pre-existing cardiovascular disease such as nyha ≥ iii sickle cell anemia patients presenting with any clinical, laboratory or radiological signs of tumor-progression patient receiving active treatment with small molecules, including tyrosine kinases-inhibitors (e.g. ibrutinib), proteosome-inhibitors (e.g. bortezomib), bcl-2- inhibitors (e.g. venetoclax), phosphoinositid-3-kinase- inhibors (e.g. idelalisib) known hypersensitivity to any of the components included in the covac-1 vaccine pre-existing auto-immune disease except for hashimoto thyroiditis and mild (not requiring immunosuppressive treatment) psoriasis intention of receiving one dose of an already approved vaccine against sars-cov-2 before day 56

pregnant or lactating females participation in any clinical trial with intake of any nonregistered vaccine product any concomitant disease affecting the effect of the therapeutic vaccine or interfering with the study primary endpoint: active infection psychiatric disorders known systemic anaphylaxis prior or current infection with sars-cov-2 as assessed by medical history and/or by throat/nose swab (pcr) or serologically documented immunization against sarscov- 2 (after infection or vaccination) persisting symptoms developed after sars-cov-2 vaccination with an approved vaccine product at study inclusion history of guillain-barré syndrome hiv infection, chronic or active hepatitis b or c history of relevant cns pathology or current relevant cns pathology (e.g. seizure, paresis, aphasia, cerebrovascular ischemia/haemorrhage, severe brain injuries, dementia, parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder, excluding febrile seizures as child) baseline laboratory cd4+ t cell count < 100 μl the following pre-existing medical conditions: chronic liver failure defined as child-pugh score ≥b chronic renal failure defined as gfr <40 ml/min/1,73m2 serious pre-existing cardiovascular disease such as nyha ≥ iii sickle cell anemia patients presenting with any clinical, laboratory or radiological signs of tumor-progression patient receiving active treatment with small molecules, including tyrosine kinases-inhibitors (e.g. ibrutinib), proteosome-inhibitors (e.g. bortezomib), bcl-2- inhibitors (e.g. venetoclax), phosphoinositid-3-kinase- inhibors (e.g. idelalisib) known hypersensitivity to any of the components included in the covac-1 vaccine pre-existing auto-immune disease except for hashimoto thyroiditis and mild (not requiring immunosuppressive treatment) psoriasis intention of receiving one dose of an already approved vaccine against sars-cov-2 before day 56

1. pregnant or lactating females 2. participation in any clinical trial with intake of any nonregistered vaccine product 3. any concomitant disease affecting the effect of the therapeutic vaccine or interfering with the study primary endpoint: - active infection - psychiatric disorders - known systemic anaphylaxis 4. prior or current infection with sars-cov-2 as assessed by medical history and/or by throat/nose swab (pcr) or serologically documented immunization against sarscov- 2 (after infection or vaccination) 5. persisting symptoms developed after sars-cov-2 vaccination with an approved vaccine product at study inclusion 6. history of guillain-barré syndrome 7. hiv infection, chronic or active hepatitis b or c 8. history of relevant cns pathology or current relevant cns pathology (e.g. seizure, paresis, aphasia, cerebrovascular ischemia/haemorrhage, severe brain injuries, dementia, parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder, excluding febrile seizures as child) 9. baseline laboratory cd4+ t cell count < 100 μl 10. the following pre-existing medical conditions: - chronic liver failure defined as child-pugh score ≥b - chronic renal failure defined as gfr <40 ml/min/1,73m2 - serious pre-existing cardiovascular disease such as nyha ≥ iii - sickle cell anemia 11. patients presenting with any clinical, laboratory or radiological signs of tumor-progression 12. patient receiving active treatment with small molecules, including tyrosine kinases-inhibitors (e.g. ibrutinib), proteosome-inhibitors (e.g. bortezomib), bcl-2- inhibitors (e.g. venetoclax), phosphoinositid-3-kinase- inhibors (e.g. idelalisib) 13. known hypersensitivity to any of the components included in the covac-1 vaccine 14. pre-existing auto-immune disease except for hashimoto thyroiditis and mild (not requiring immunosuppressive treatment) psoriasis 15. intention of receiving one dose of an already approved vaccine against sars-cov-2 before day 56

1. pregnant or lactating females 2. participation in any clinical trial with intake of any nonregistered vaccine product 3. any concomitant disease affecting the effect of the therapeutic vaccine or interfering with the study primary endpoint: - active infection - psychiatric disorders - known systemic anaphylaxis 4. prior or current infection with sars-cov-2 as assessed by medical history and/or by throat/nose swab (pcr) or serologically documented immunization against sarscov- 2 (after infection or vaccination) 5. persisting symptoms developed after sars-cov-2 vaccination with an approved vaccine product at study inclusion 6. history of guillain-barré syndrome 7. hiv infection, chronic or active hepatitis b or c 8. history of relevant cns pathology or current relevant cns pathology (e.g. seizure, paresis, aphasia, cerebrovascular ischemia/haemorrhage, severe brain injuries, dementia, parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder, excluding febrile seizures as child) 9. baseline laboratory cd4+ t cell count < 100 μl 10. the following pre-existing medical conditions: - chronic liver failure defined as child-pugh score ≥b - chronic renal failure defined as gfr <40 ml/min/1,73m2 - serious pre-existing cardiovascular disease such as nyha ≥ iii - sickle cell anemia 11. patients presenting with any clinical, laboratory or radiological signs of tumor-progression 12. patient receiving active treatment with small molecules, including tyrosine kinases-inhibitors (e.g. ibrutinib), proteosome-inhibitors (e.g. bortezomib), bcl-2- inhibitors (e.g. venetoclax), phosphoinositid-3-kinase- inhibors (e.g. idelalisib) 13. known hypersensitivity to any of the components included in the covac-1 vaccine 14. pre-existing auto-immune disease except for hashimoto thyroiditis and mild (not requiring immunosuppressive treatment) psoriasis 15. intention of receiving one dose of an already approved vaccine against sars-cov-2 before day 56